STAT1 and prostate cancer: To determine the potential therapeutic role of SHP2 depletion in prostate cancer, additional studies are needed to clarify (i) whether SHP2 depletion also upregulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in vivo, (ii) whether PD-L1 expression in prostate cancer predicts the response to anti-PD-L1 or anti-PD-1 therapy, and (iii) whether SHP2 depletion enhances the efficacy of therapies targeting PD-1/PD-L1 pathway.